サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1760537

塩酸ゲムシタビンの世界市場レポート 2025年

Gemcitabine Hydrochloride Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
塩酸ゲムシタビンの世界市場レポート 2025年
出版日: 2025年07月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

塩酸ゲムシタビン市場規模は、今後数年間で力強い成長が見込まれます。2029年には11億米ドルに成長し、CAGRは7.0％となります。予測期間の成長は、世界のがん罹患率の増加、高齢化、非小細胞肺がん罹患率の上昇、膵臓がんおよび転移性乳がん症例の急増、併用化学療法の対象となる患者数の増加に起因すると考えられます。この期間に予想される主な動向としては、新しい薬剤の組み合わせや適応を検討する進行中の臨床試験、シスプラチン、カルボプラチン、パクリタキセルを含む薬剤との併用療法における使用拡大、ドラッグデリバリーシステムの進歩、毒性軽減を目的とした製剤技術の改善、医薬品製造工程における自動化の進展などが挙げられます。

乳がんの罹患率の増加は、今後数年間の塩酸ゲムシタビン市場の成長を促進すると予想されます。乳がんは乳房の細胞、一般的には乳管や乳腺に発生します。平均寿命が延びるにつれて、乳がんのリスクも高まりますが、これは主に加齢に伴って遺伝子変異が蓄積する可能性が高くなるためです。塩酸ゲムシタビンは、DNAの複製を阻害することにより、異常細胞の急速な増殖を遅らせるという、乳がん治療において重要な役割を果たしています。例えば、2024年9月、オーストラリア政府は、2022年にオーストラリアで推定2万640人が乳がんと診断されると報告しました。85歳までに乳がんと診断される全生涯リスクは、男性では15人に1人（6.7％）-668人に1人（0.15％）、女性では8人に1人（13％）と予測されました。このような有病率の増加は、塩酸ゲムシタビンを含む効果的な治療に対する需要の高まりを強調しています。

塩酸ゲムシタビン市場の主要企業は、治療成績を向上させるために周術期免疫療法などの革新的なアプローチを開発することにより、がん治療を前進させています。周術期免疫療法は、手術前（ネオアジュバント）と手術後（アジュバント）の両方に治療を行うことで、効果を高め、がんの再発リスクを低下させるものです。例えば、2025年3月、英国の製薬会社アストラゼネカ社はイムフィンジ（デュルバルマブ）の米国食品医薬品局（FDA）承認を取得し、筋層浸潤性膀胱がん（MIBC）に対する最初で唯一の承認された周術期免疫療法となりました。この治療プロトコールでは、手術前にイムフィンジと化学療法剤（ゲムシタビンおよびシスプラチン）を併用し、術後もイムフィンジを継続使用します。臨床試験では、この併用療法が生存率を有意に改善し、再発の可能性を減少させることが実証され、がん治療におけるこのような併用療法の革新的な可能性が強調されました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の塩酸ゲムシタビンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の塩酸ゲムシタビン市場：成長率分析
  • 世界の塩酸ゲムシタビン市場の実績：規模と成長、2019年～2024年
  • 世界の塩酸ゲムシタビン市場の予測：規模と成長、2024年～2029年、2034年
  • 世界の塩酸ゲムシタビン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の塩酸ゲムシタビン市場：製品タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 注射
  • ソリューション
  • その他の製品タイプ
  • 世界の塩酸ゲムシタビン市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 静脈注射
  • 皮下注射
  • 筋肉内注射
  • 世界の塩酸ゲムシタビン市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 専門クリニック
  • 世界の塩酸ゲムシタビン市場：用途別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 膵臓がん
  • 非小細胞肺がん
  • 膀胱がん
  • 乳がん
  • 卵巣がん
  • その他の用途
  • 世界の塩酸ゲムシタビン市場、注射のサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 単回投与バイアル
  • マルチドーズバイアル
  • プレフィルドシリンジ
  • 世界の塩酸ゲムシタビン市場、ソリューションのサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • すぐに使える液体溶液
  • 希釈用濃縮溶液
  • 経口液剤
  • 世界の塩酸ゲムシタビン市場、その他の製品タイプのサブセグメンテーション、タイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 凍結乾燥粉末
  • カプセル
  • その他の化学療法剤との併用製剤

第7章 地域別・国別分析

  • 世界の塩酸ゲムシタビン市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
  • 世界の塩酸ゲムシタビン市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 塩酸ゲムシタビン市場：競合情勢
  • 塩酸ゲムシタビン市場：企業プロファイル
    • Fresenius Kabi Overview, Products and Services, Strategy and Financial Analysis
    • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
    • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Mylan NV Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Accord Healthcare
  • Sandoz Group AG
  • Sun Pharmaceutical Industries Ltd.
  • Apotex Inc.
  • Dr. Reddy's Laboratories
  • Cipla Ltd.
  • Amneal Pharmaceuticals
  • Alkem Laboratories
  • Gland Pharma Ltd.
  • Strides Pharma Science Ltd.
  • Shilpa Medicare Ltd.
  • ScinoPharm Taiwan Ltd.
  • Orchid Pharma Ltd.
  • Arevipharma GmbH
  • Qilu Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 塩酸ゲムシタビン市場2029年：新たな機会を提供する国
  • 塩酸ゲムシタビン市場2029年：新たな機会を提供するセグメント
  • 塩酸ゲムシタビン市場2029年：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35414

Gemcitabine hydrochloride is a synthetic nucleoside analog that disrupts DNA synthesis, thereby preventing cell division. Due to its ability to integrate into DNA strands and halt replication, it is widely used in research focused on cellular replication. Once inside the cell, gemcitabine is phosphorylated into its active form, becomes incorporated into DNA, causes chain termination, and ultimately initiates programmed cell death.

The primary product types of gemcitabine hydrochloride include injections, solutions, and other forms. The injection form is delivered directly into the bloodstream using a syringe or intravenous (IV) method and may also be administered subcutaneously or intramuscularly. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and specialty clinics. It is used in the treatment of various cancers, including pancreatic cancer, non-small cell lung cancer, bladder cancer, breast cancer, ovarian cancer, and others.

The gemcitabine hydrochloride market research report is one of a series of new reports from The Business Research Company that provides gemcitabine hydrochloride market statistics, including gemcitabine hydrochloride industry global market size, regional shares, competitors with a gemcitabine hydrochloride market share, detailed gemcitabine hydrochloride market segments, market trends and opportunities, and any further data you may need to thrive in the gemcitabine hydrochloride industry. This gemcitabine hydrochloride market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gemcitabine hydrochloride market size has grown strongly in recent years. It will grow from $0.78 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 7.3%. The growth observed during the historic period can be attributed to several factors, including the expansion of early-stage cancer detection programs, the development of oncology drug distribution networks, increased access to treatment through both public and private healthcare systems, greater inclusion of gemcitabine hydrochloride in hospital oncology formularies, and a general rise in global healthcare expenditures.

The gemcitabine hydrochloride market size is expected to see strong growth in the next few years. It will grow to $1.10 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The projected growth in the forecast period can be attributed to the increasing global prevalence of cancer, an aging population, a rising incidence of non-small cell lung cancer, a surge in pancreatic and metastatic breast cancer cases, and a growing number of patients eligible for combination chemotherapy. Key trends expected during this period include ongoing clinical trials investigating new drug combinations and indications, expanded use in combination therapies with agents including cisplatin, carboplatin, and paclitaxel, advancements in drug delivery systems, improved formulation technologies aimed at reducing toxicity, and increased automation in pharmaceutical manufacturing processes.

The increasing incidence of breast cancer is expected to drive the growth of the gemcitabine hydrochloride market in the coming years. Breast cancer originates in the cells of the breast, typically within the milk ducts or glands. As life expectancy rises, the risk of breast cancer also increases, primarily due to the greater likelihood of genetic mutations accumulating with age. Gemcitabine hydrochloride plays a vital role in breast cancer treatment by disrupting DNA replication, thereby slowing the rapid proliferation of abnormal cells. For example, in September 2024, the Australian Government reported that an estimated 20,640 individuals in Australia were expected to be diagnosed with breast cancer in 2022, including 212 males and 20,428 females. The overall lifetime risk of being diagnosed with breast cancer by age 85 was projected at 1 in 15 (6.7%)-1 in 668 (0.15%) for men and 1 in 8 (13%) for women. This rising prevalence underscores the growing demand for effective treatments, including gemcitabine hydrochloride.

Leading companies in the gemcitabine hydrochloride market are advancing cancer treatment by developing innovative approaches such as perioperative immunotherapy to improve therapeutic outcomes. Perioperative immunotherapy involves administering treatment both before (neoadjuvant) and after (adjuvant) surgery to enhance effectiveness and lower the risk of cancer recurrence. For example, in March 2025, AstraZeneca, a UK-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Imfinzi (durvalumab), marking it as the first and only approved perioperative immunotherapy for muscle-invasive bladder cancer (MIBC). The treatment protocol includes a combination of Imfinzi with chemotherapy agents-gemcitabine and cisplatin-prior to surgery, followed by continued use of Imfinzi post-surgery. Clinical trials demonstrated that this approach significantly improved survival rates and reduced the includinglihood of recurrence, highlighting the transformative potential of such combination therapies in oncology.

In December 2024, Cheplapharm, a pharmaceutical company based in Germany, acquired Gemzar from Eli Lilly for an undisclosed amount. This acquisition enhances Cheplapharm's oncology portfolio by adding Gemzar, a well-established chemotherapy drug used to treat a range of cancers, including non-small cell lung cancer, pancreatic cancer, and breast cancer. Eli Lilly and Company is a US-based manufacturer of gemcitabine hydrochloride, commonly known as Gemzar.

Major players in the gemcitabine hydrochloride market are Fresenius Kabi, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Mylan NV, Accord Healthcare, Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Apotex Inc., Dr. Reddy's Laboratories, Cipla Ltd., Amneal Pharmaceuticals, Alkem Laboratories, Gland Pharma Ltd., Strides Pharma Science Ltd., Shilpa Medicare Ltd., ScinoPharm Taiwan Ltd., Orchid Pharma Ltd., Arevipharma GmbH, and Qilu Pharmaceutical Co. Ltd.

North America was the largest region in the gemcitabine hydrochloride market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gemcitabine hydrochloride report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gemcitabine hydrochloride market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gemcitabine hydrochloride market consists of sales of pharmaceutical intermediates, generic injectable drugs, and formulation development kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gemcitabine Hydrochloride Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gemcitabine hydrochloride market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gemcitabine hydrochloride ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gemcitabine hydrochloride market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product Type: Injection; Solution; Other Product Types
  • 2) By Route of Administration: Intravenous Injection; Subcutaneous Injection; Intramuscular Injection
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics
  • 4) By Application: Pancreatic Cancer; Non-Small Cell Lung Cancer; Bladder Cancer; Breast Cancer; Ovarian Cancer; Other Applications
  • Subsegments:
  • 1) By Injection: Single-Dose Vials; Multi-Dose Vials; Prefilled Syringes
  • 2) By Solution: Ready-To-Use Liquid Solutions; Concentrated Solutions For Dilution; Oral Liquid Formulations
  • 3) By Other Product Types: Lyophilized Powder; Capsules; Combination Formulations With Other Chemotherapeutic Agents
  • Companies Mentioned: Fresenius Kabi; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Intas Pharmaceuticals Ltd.; Mylan NV
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gemcitabine Hydrochloride Market Characteristics

3. Gemcitabine Hydrochloride Market Trends And Strategies

4. Gemcitabine Hydrochloride Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gemcitabine Hydrochloride Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Gemcitabine Hydrochloride PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Gemcitabine Hydrochloride Market Growth Rate Analysis
  • 5.4. Global Gemcitabine Hydrochloride Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Gemcitabine Hydrochloride Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Gemcitabine Hydrochloride Total Addressable Market (TAM)

6. Gemcitabine Hydrochloride Market Segmentation

  • 6.1. Global Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Injection
  • Solution
  • Other Product Types
  • 6.2. Global Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intravenous Injection
  • Subcutaneous Injection
  • Intramuscular Injection
  • 6.3. Global Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Specialty Clinics
  • 6.4. Global Gemcitabine Hydrochloride Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pancreatic Cancer
  • Non-Small Cell Lung Cancer
  • Bladder Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Other Applications
  • 6.5. Global Gemcitabine Hydrochloride Market, Sub-Segmentation Of Injection, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Single-Dose Vials
  • Multi-Dose Vials
  • Prefilled Syringes
  • 6.6. Global Gemcitabine Hydrochloride Market, Sub-Segmentation Of Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ready-To-Use Liquid Solutions
  • Concentrated Solutions For Dilution
  • Oral Liquid Formulations
  • 6.7. Global Gemcitabine Hydrochloride Market, Sub-Segmentation Of Other Product Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lyophilized Powder
  • Capsules
  • Combination Formulations With Other Chemotherapeutic Agents

7. Gemcitabine Hydrochloride Market Regional And Country Analysis

  • 7.1. Global Gemcitabine Hydrochloride Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Gemcitabine Hydrochloride Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gemcitabine Hydrochloride Market

  • 8.1. Asia-Pacific Gemcitabine Hydrochloride Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gemcitabine Hydrochloride Market

  • 9.1. China Gemcitabine Hydrochloride Market Overview
  • 9.2. China Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gemcitabine Hydrochloride Market

  • 10.1. India Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gemcitabine Hydrochloride Market

  • 11.1. Japan Gemcitabine Hydrochloride Market Overview
  • 11.2. Japan Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gemcitabine Hydrochloride Market

  • 12.1. Australia Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gemcitabine Hydrochloride Market

  • 13.1. Indonesia Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gemcitabine Hydrochloride Market

  • 14.1. South Korea Gemcitabine Hydrochloride Market Overview
  • 14.2. South Korea Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gemcitabine Hydrochloride Market

  • 15.1. Western Europe Gemcitabine Hydrochloride Market Overview
  • 15.2. Western Europe Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gemcitabine Hydrochloride Market

  • 16.1. UK Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gemcitabine Hydrochloride Market

  • 17.1. Germany Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gemcitabine Hydrochloride Market

  • 18.1. France Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gemcitabine Hydrochloride Market

  • 19.1. Italy Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gemcitabine Hydrochloride Market

  • 20.1. Spain Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gemcitabine Hydrochloride Market

  • 21.1. Eastern Europe Gemcitabine Hydrochloride Market Overview
  • 21.2. Eastern Europe Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gemcitabine Hydrochloride Market

  • 22.1. Russia Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gemcitabine Hydrochloride Market

  • 23.1. North America Gemcitabine Hydrochloride Market Overview
  • 23.2. North America Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gemcitabine Hydrochloride Market

  • 24.1. USA Gemcitabine Hydrochloride Market Overview
  • 24.2. USA Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gemcitabine Hydrochloride Market

  • 25.1. Canada Gemcitabine Hydrochloride Market Overview
  • 25.2. Canada Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gemcitabine Hydrochloride Market

  • 26.1. South America Gemcitabine Hydrochloride Market Overview
  • 26.2. South America Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gemcitabine Hydrochloride Market

  • 27.1. Brazil Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gemcitabine Hydrochloride Market

  • 28.1. Middle East Gemcitabine Hydrochloride Market Overview
  • 28.2. Middle East Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gemcitabine Hydrochloride Market

  • 29.1. Africa Gemcitabine Hydrochloride Market Overview
  • 29.2. Africa Gemcitabine Hydrochloride Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Gemcitabine Hydrochloride Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Gemcitabine Hydrochloride Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gemcitabine Hydrochloride Market Competitive Landscape And Company Profiles

  • 30.1. Gemcitabine Hydrochloride Market Competitive Landscape
  • 30.2. Gemcitabine Hydrochloride Market Company Profiles
    • 30.2.1. Fresenius Kabi Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Mylan NV Overview, Products and Services, Strategy and Financial Analysis

31. Gemcitabine Hydrochloride Market Other Major And Innovative Companies

  • 31.1. Accord Healthcare
  • 31.2. Sandoz Group AG
  • 31.3. Sun Pharmaceutical Industries Ltd.
  • 31.4. Apotex Inc.
  • 31.5. Dr. Reddy's Laboratories
  • 31.6. Cipla Ltd.
  • 31.7. Amneal Pharmaceuticals
  • 31.8. Alkem Laboratories
  • 31.9. Gland Pharma Ltd.
  • 31.10. Strides Pharma Science Ltd.
  • 31.11. Shilpa Medicare Ltd.
  • 31.12. ScinoPharm Taiwan Ltd.
  • 31.13. Orchid Pharma Ltd.
  • 31.14. Arevipharma GmbH
  • 31.15. Qilu Pharmaceutical Co. Ltd.

32. Global Gemcitabine Hydrochloride Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gemcitabine Hydrochloride Market

34. Recent Developments In The Gemcitabine Hydrochloride Market

35. Gemcitabine Hydrochloride Market High Potential Countries, Segments and Strategies

  • 35.1 Gemcitabine Hydrochloride Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Gemcitabine Hydrochloride Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Gemcitabine Hydrochloride Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer